Does knock-down of superoxide dismutase 1 sensitize cisplatin-resistant human ovarian cancer cells?
Specifically targeting SOD1 could lead to sensitization of cisplatin-resistant ovarian cancer cells, and SOD1 may be used as a potential target for chemosensitizers.
Multiple targeting of GBM sub-populations may, therefore, help inform novel therapeutic approaches.